First Pharmacogenomics Study on COVID-19 Vaccine Reactions
Scientists surveyed more than 17,000 participants from the Helix DNA Discovery Project and Healthy Nevada Project, who had their DNA previously sequenced with the Helix Exome+ assay, and asked respondents about their specific reactions to the COVID-19 vaccine, in order to perform a genome wide association study (GWAS).
The study identified that participants with the HLA-A*03:01 allele who received the Pfizer-BioNTech (Pfizer) vaccine are approximately twice as likely to have severe or extreme difficulties after receiving the vaccine (defined as reactions that would severely interfere with daily routine like fever and chills), than those without the allele. In contrast, the signal was very weak for those receiving the Moderna vaccine and did not approach genome-wide significance, despite a similar sample size. This held true across age groups, sex, and whether the person had a personal history of COVID-19 prior to the vaccination.
Learn more about how to integrate genomics into everyday patient care, as well as, the pioneering research that health systems across the US are partnering with Helix to publish here.
Helix is the leading population genomics and viral surveillance company operating at the intersection of clinical care, research, and data analytics.